| Oct 2026 | Testosterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone acetate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone cypionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone decanoate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone enanthate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone isocaproate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone phenyl propionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone propionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Testosterone undecanoate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Trenbolone acetate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Trenbolone enanthate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Desogestrel | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Dienogest | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Dydrogesterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Ethinyl estradiol | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estradiol | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estradiol benzoate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estradiol cypionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estradiol hemihydrate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estradiol phenyl propionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estradiol valerate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Esterified estrogens | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estrone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estrone sodium sulfate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Hydroxyprogesterone caproate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Levonorgestrel | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Medroxyprogesterone acetate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Norethisterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Norethisterone acetate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Norethisterone enanthate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Progesterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Estriol | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Aldosterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Allylestrenol | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Boldenone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Boldenone cypionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Boldenone undecylenate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Clascoterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Spironolactone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Danazol | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Docosahexaenoic acid | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Dehydroepiandrosterone (DHEA) | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Drostanolone propionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Drostanolone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Equilenin | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Methyltestosterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Ethisterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Fluoxymesterone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Lynestrenol | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Metandienone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Nandrolone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Nandrolone decanoate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Nandrolone phenyl propionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Ospemifene | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Oxandrolone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Oxymetholone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Stanolone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Ulipristal acetate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Drospirenone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Dehydroepiandrosterone enanthate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Nandrolone cypionate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Nandrolone undecanoate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Norethisterone diacetate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Mifepristone | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Blonaserin | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Cyanocobalamin (vitamin B12) | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Apixaban | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Artemether | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Atorvastatin | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Dapagliflozin | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Deferasirox | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Empagliflozin | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Fexofenadine hydrochloride | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Ketoconazole | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Linagliptin | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Montelukast | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Olmesartan | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Rivaroxaban | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Rosuvastatin calcium | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Sitagliptin phosphate monohydrate | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Telmisartan | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Teneligliptin hydrobromide | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Valsartan | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Minoxidil | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |
| Oct 2026 | Itraconazole | ↑ NEW PLANT | Public hearing held | — | EIA executive summary, GPCB |